Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

To find out if adding medication can help treat or prevent lymphedema and/or fibrosis related to radiation therapy, in survivors of head and neck cancer. Researchers will compare these drugs to find the most effective therapy for preventing or limiting these side effects.

Start Date18 Sep 2025

Sponsor / Collaborator-

CTR20251551

/ CompletedNot Applicable

酮洛芬贴剂在健康人群中的生物等效性试验

[Translation] Bioequivalence study of ketoprofen patch in healthy people

以健康受试者为研究对象，以北京福元医药股份有限公司持有的酮洛芬贴剂（规格：40 mg/贴(10 cm×14 cm)）为受试制剂，以久光製薬株式会社生产的酮洛芬贴剂（商品名：MOHRUS®，规格：40 mg/贴(10 cm×14 cm)）为参比制剂，比较两种制剂在健康受试者体内的吸收速度和吸收程度，评价两种制剂的生物等效性。观察受试制剂酮洛芬贴剂和参比制剂酮洛芬贴剂在中国健康受试者中的安全性、皮肤反应性和黏附性。

[Translation]

Healthy subjects were used as research subjects, ketoprofen patches (specification: 40 mg/patch (10 cm×14 cm)) owned by Beijing Fuyuan Pharmaceutical Co., Ltd. were used as test preparations, and ketoprofen patches (trade name: MOHRUS®, specification: 40 mg/patch (10 cm×14 cm)) produced by Hisamitsu Pharmaceutical Co., Ltd. were used as reference preparations. The absorption rate and extent of the two preparations in healthy subjects were compared, and the bioequivalence of the two preparations was evaluated. To observe the safety, skin reactivity and adhesion of the test preparation ketoprofen patch and the reference preparation ketoprofen patch in healthy Chinese subjects.

Start Date10 May 2025

Sponsor / Collaborator

Beijing Winsunny Pharmaceutical Co., Ltd.

CTR20250998

/ CompletedNot Applicable

酮洛芬凝胶人体生物等效性研究

[Translation] Study on the bioequivalence of ketoprofen gel in healthy volunteers

主要目的：比较空腹给药条件下深圳珐玛易药品科技有限公司提供、湖南派格兰药业有限公司生产的酮洛芬凝胶（规格：2.5%（20g∶ 0.5g））与A.Menarini Industrie Farmaceutiche Riunite S.r.l.持证的酮洛芬凝胶（商品名：法斯通®（Fastum®）；规格：1g∶ 0.025g）在中国健康人群吸收程度和吸收速度的差异。次要目的：评价空腹条件下，深圳珐玛易药品科技有限公司提供、湖南派格兰药业有限公司生产的酮洛芬凝胶（规格：2.5%（20g∶ 0.5g））与A.Menarini Industrie Farmaceutiche Riunite S.r.l.持证的酮洛芬凝胶（商品名：法斯通®（Fastum®）；规格：1g∶ 0.025g）在健康研究参与者体内的安全性。

[Translation]

Primary objective: To compare the differences in the extent and rate of absorption of ketoprofen gel (specification: 2.5% (20g: 0.5g)) provided by Shenzhen PharmaEasy Pharmaceutical Technology Co., Ltd. and produced by Hunan Paiglan Pharmaceutical Co., Ltd. and ketoprofen gel (trade name: Fastum®; specification: 1g: 0.025g) licensed by A.Menarini Industrie Farmaceutiche Riunite S.r.l.) in healthy Chinese people under fasting conditions. Secondary objective: To evaluate the safety of ketoprofen gel (specification: 2.5% (20g: 0.5g)) provided by Shenzhen PharmaEasy Pharmaceutical Technology Co., Ltd. and produced by Hunan Paiglan Pharmaceutical Co., Ltd. and ketoprofen gel (trade name: Fastum®; specification: 1g: 0.025g) licensed by A.Menarini Industrie Farmaceutiche Riunite S.r.l. under fasting conditions in healthy study participants.

Start Date11 Apr 2025

Sponsor / Collaborator

Shen Zhen Fa Ma Yi Yao Pin Ke Ji You Xian Gong Si

100 Clinical Results associated with Ketoprofen

100 Translational Medicine associated with Ketoprofen

100 Patents (Medical) associated with Ketoprofen

11,423

Literatures (Medical) associated with Ketoprofen

01 Nov 2025·JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY

Effect of microplastics on the photodegradation of high-consumption drugs under simulated sunlight: The critical role of aging and reactive oxygen species

Author: Kyzas, George Z. ; Kalaronis, Dimitrios ; Bikiaris, Dimitrios N. ; Evgenidou, Eleni ; Lambropoulou, Dimitra A. ; Teknetzi, Aikaterini ; Vourlias, George

The main aim of this study was to examine the effect of polypropylene (PP), poly(ethylene terephthalate) (PET), and poly(lactic acid) (PLA) microplastics (MPs) on the photolytic degradation of a mixture of seven commonly used pharmaceuticals under simulated solar irradiation (SSL).The target mixture included four common antibiotics (metronidazole, trimethoprim, indomethacin, isoniazid), two non-steroidal anti-inflammatory drugs (diclofenac, ketoprofen), and one antihypertensive drug (valsartan).The selected MPs were aged using three different procedures: (i) SSL light, (ii) UV/H₂O₂, and (iii) Fenton reagent.The effect of MPs mass concentration was examined using only the pristine MPs, while the aging effect was evaluated for the three different aged MPs for each polymer type.The results demonstrated that the presence of MPs generally accelerates the photolytic degradation of the drugs, and increasing their concentration further enhances the reaction rate.Aging of the MPs also appeared to enhance the photodegradation of the selected pharmaceuticals.Among the various aging processes applied, UV/H2O2 had the greatest impact on surface alteration of the MPs and consequently, UV/H₂O₂-aged PET MPs exhibited the highest influence on the photolytic degradation of the drugs.To gain a deeper understanding of the mechanism behind the photolytic degradation of the examined pharmaceuticals, a systematic characterization of pristine and aged MPs was conducted using Fourier transformed IR spectroscopy (FTIR), XPS, and SEM-energy dispersive X-ray spectroscopy (SEM-EDX) techniques, which detected the formation of oxygen containing groups on the MPs' surfaces.Finally, scavenger experiments were also conducted to explore the formation and role of reactive oxygen species (singlet oxygen, superoxide anions, and hydroxyl radicals) in the degradation of the target compounds

01 Nov 2025·TALANTA

Development of CE-MS/MS method for unravelling nonsteroidal anti-inflammatory drugs as potential adulterants of Boswellia serrata extract

Article

Author: Bařinka, Filip ; Nováková, Lucie ; Moreno-González, David ; Jáč, Pavel ; Kosolapov, Dmytro ; Gazárková, Taťána

The CE-MS/MS method for the analysis of boswellic acids, natural compounds with anti-inflammatory activity, and nonsteroidal anti-inflammatory drugs (NSAIDs) as potential adulterants of dietary supplements with Boswellia serrata extract is presented for the first time. An aqueous-organic background electrolyte comprising 40 mmol/L ammonium acetate (pH 8.5), methanol, and acetonitrile (5:1:4, v/v/v) was used for the separation of boswellic acids and thirteen NSAIDs in negative electrospray ionization mode. Design-of-experiments-guided optimization of Agilent Jet Stream ion source parameters and adjustments to the sheath liquid composition were conducted to improve sensitivity and prevent capillary breakage inside the nebulizer. The CE-MS/MS method was validated for diclofenac, flurbiprofen, ibuprofen, ketoprofen, phenylbutazone, salicylic acid, and carprofen, meeting the ICH M10 guideline requirements for accuracy, precision, matrix effects, and recovery. The lower limits of quantification ranged from 0.04 to 4 μg/mL for all NSAIDs, providing sufficient sensitivity to detect adulteration. The application of the method to dietary supplements revealed no evidence of NSAID adulteration while highlighting quantitative variations in boswellic acid profiles. Further analysis using CE-HRMS with data-dependent acquisition workflow enabled the identification of additional natural triterpenoids and undeclared compounds, such as citric acid and ascorbic acid.

01 Sep 2025·AQUATIC TOXICOLOGY

Contamination of water with drugs - the response of phytoplankton

Article

Author: Krawczyk, Barbara ; Kaźmierczak, Andrzej ; Czarny-Krzymińska, Karolina ; Szczukocki, Dominik

Human xenobiotic emissions exert a notable effect on aquatic organisms. However, there is a paucity of information concerning the chronic effects of drugs on aquatic microorganisms. Furthermore, the majority of studies to date have considered the toxicity of individual compounds in isolation rather than in complex mixtures found in the environment. The present investigation sought to assess the chronic impact of amoxicillin, bisoprolol, diclofenac, ketoprofen, sulfadiazine, and tramadol on three species of aquatic primary producers: Chlorella vulgaris, Desmodesmus armatus, and Trichormus variabilis for both individual compounds and their mixture. The obtained findings demonstrated significant inhibition of the growth of all tested strains, alteration in antioxidant enzyme activity, and morphological changes in their cells. The nature of the effects of the compounds in the tested mixture was additive. Furthermore, the ecological risk associated with exposure to the tested substances was assessed. The risk was determined to be high for ketoprofen and drugs mixture, medium for amoxicillin, diclofenac, and sulfadiazine, and low for bisoprolol and tramadol. The results of this study have revealed the ecotoxicological risks posed by the tested drugs to photosynthetic microorganisms, and have also offered insights into the biochemistry and cell morphology of the microorganisms in question. In addition, the findings of this study indicate that the exclusive reliance on the EC₅₀ parameter in the evaluation of the impact of xenobiotics on non-target organisms represents a remarkably constrained approach. This is attributable to the fact that it fails to provide insight into the changes that occur at the cellular level.

News (Medical) associated with Ketoprofen

27 Jun 2023

·m.economictimes.com

CORONA remedies buys Sanofi India's ortho brand Myoril

Ahmedabad-based pharmaceutical company CORONA Remedies has acquired the muscle relaxant brand Myoril from Sanofi India for Rs234 crore. The acquisition includes Myoril and its extensions. This acquisition comes after Corona's previous acquisitions of drug brands from GlaxoSmithKline and Abbott India. Myoril, with annual sales of Rs38 crore and a growth rate of 6.8%, will strengthen Corona's presence in the growing muscle relaxant market in India, which is valued at Rs1,626 crore. Ahmedabad-based pharmaceutical company CORONA Remedies has acquired leading muscle relaxant brand Myoril from Sanofi India, for Rs234 crore. Corona has acquired Myoril (Thiocolchicoside) and its extensions such as Myoril Plus (Ketoprofen + Thiocolchicoside), said people aware of the development. Another domestic pharmaceutical majors Torrent Pharma and Eris Lifesciences were also in the race to acquire these orthopaedic brands, said sources. When contacted, a Sanofi spokesperson confirmed the development. The acquisition of the Myoril brand for the Indian market is effective from June 28, 2023, added the spokesperson. Corona Remedies is backed by domestic PE fund ChrysCapital which owns about 30% stake with an investment of about Rs670 crore ($90 million). In 2017, Corona had acquired four drug brands of GlaxoSmithKline - Dilo-BM, Dilo-DX, Stelbid and Vitneurin. Two brands from Abbott India - Obimet and Thyrocab range of products (for diabetes and hyperthyroidism) were also acquired in 2018. The muscle relaxant market in India is valued at Rs. 1,626 crore and it is growing at 13%. Myoril has annual sales of Rs. 38 crore and a growth of 6.8%, according to IQVIA May 2023 data. Sanofi India has been divesting its non-core products as part of concentrating on its core areas such as chronic diseases. As part of the transformation, Sanofi India changed its organisation structure from eight Business Units (BUs) to a focused group of three BUs - Diabetes; Consumer Healthcare; and Transplants & Cardiology, said the company's annual report. Earlier, Sanofi India had sold its nutraceutical portfolio consisting of 16 brands and 30 stock-keeping units (SKUs) to a consortium of Universal Medicare-Kedaara Capital for Rs587 crore in 2021. In the same year, Sanofi India had sold its skin care brands - Soframycin and Sofradex brands to Encube Ehticals for a total consideration of Rs 125 crore. In May, Sanofi India demerged its consumer healthcare business to a wholly owned subsidiary Sanofi Consumer Healthcare India as a value-driven move to accelerate growth for both the pharmaceuticals business and consumer healthcare business in India. There are interest from Indian pharma companies for a few of Sanofi's consumer brands such as DePURA and Combiflam, added sources. The Indian pharmaceutical industry has been growing at an average of 10% over the past five years. In 2022, the industry grew by 6.5%, adding nearly Rs12,000 crore of incremental sales. The demand for acute therapies increased, while most chronic therapies like diabetes and cardiovascular treatments remained relatively steady, said the Sanofi India report. The IQVIA Prognosis Report (2022) projects that the Indian pharmaceuticals market is expected to grow at a CAGR 9.2% between 2021-26 and reach a market size of Rs2,95,100 crore by 2026. The rapid expansion of the e-pharmacy sector, expansion of co-marketing agreements, coupled with the introduction of new OTC regulations will also be a growth driver till 2026.

AcquisitionDrug Approval

17 Apr 2023

·www.drugs.com

Get Pain Relief With the Most Common Arthritis Medications

MONDAY, April 17, 2023 -- Arthritis is a common disease that causes pain and inflammation in different body joints, making it difficult to enjoy everyday tasks and physical activity. Fortunately, there are many different medications for arthritis. Depending on what type of arthritis you have and its severity, an arthritis medication may help you manage pain and other symptoms. Here is a breakdown of the most common arthritis medications, how they work and their potential side effects. The Arthritis Foundation lists the following as the medications used to treat arthritis: Analgesics including acetaminophen (Tylenol) and opioids Nonsteroidal anti-inflammatory drugs (NSAIDs) Corticosteroids Disease-modifying antirheumatic drugs (DMARDs) including biologics and targeted DMARDs Analgesics The Arthritis Foundation reports that analgesics may help with mild to moderate pain, but they will not help with the inflammation associated with arthritis. Analgesics work in the nervous system and alter how your brain perceives pain. They can be used to treat the pain associated with any type of arthritis, although more effective options are available. Analgesics can be opioid, non-opioid or a combination. Common analgesics are: Acetaminophen (Tylenol) Codeine Oxycodone Fentanyl Hydrocodone Potential side effects: Kidney damage Liver damage Addiction Constipation Gastrointestinal bleeding Use caution when taking these medications; take only as prescribed. NSAIDs NSAIDs work by blocking prostaglandin. According to the Cleveland Clinic , one role prostaglandins play is forming clots and causing inflammation at the site of an injury. NSAIDs are used to treat the pain and inflammation associated with rheumatoid arthritis and osteoarthritis . Common over-the-counter (OTC) NSAIDs are: Aspirin (Bayer, St. Joseph, Anacin, Excedrin and more) Ibuprofen (Motrin, Advil) Naproxen sodium (Aleve) Prescription NSAIDs are: Celecoxib (Celebrex) Diclofenac (Voltaren, available by brand name in topical form) Fenoprofen (Nalfon) Indomethacin (Indocin, available by brand name in liquid form) Ketorolac tromethamine (Toradol) Meclofenamate sodium (Meclomen) Diflunisal (Dolobid) Tolmetin (Tolectin) Ketoprofen (Orudis) Flurbiprofen (Ansaid) Potential side effects of NSAIDs are: Increased risk of stomach and bowel issues like ulcers and bleeding Increased risk of stroke Heart problems Stomach pain Nausea Diarrhea/constipation Corticosteroids According to the Arthritis Foundation , corticosteroids mimic cortisol, a hormone your body produces naturally. They are used to treat inflammatory types of arthritis, including rheumatoid arthritis and psoriatic arthritis. They are great for short-term relief of inflammation but are not recommended for long-term use because of their side effects. Your doctor may prescribe a lower dose if you require them for long-term use. Common corticosteroids: Prednisone (Deltasone, Prednicot, Cotolone) Prednisolone (Orapred, Omnipred) Cortisone (Cortone) Hydrocortisone (Cortef, Hydrocort) Triamcinolone (Aristocort) Dexamethasone (Decadron) Common side effects of corticosteroids: Blood sugar spikes Weight gain Bone loss Risk of cataracts High blood pressure Infections Mood changes DMARDs The Arthritis Foundation says that DMARDs work with the body to “stop or slow the disease process in inflammatory forms of arthritis.” They work by blocking inflammation. There are many different DMARDs on the market, and they all have different ways of working in the body. Conventional DMARDs work by broadly suppressing the immune system. Often they are used in combination with other therapies. Targeted DMARDs block specific pathways inside immune cells. Biologic DMARDs are produced by live cells and work on specific immune proteins called cytokines. Common DMARDs: Apremilast (Otezla) Baricitinib (Olumiant) Cyclophosphamide (Cytoxan) Cyclosporine (Gengraf, Neoral) Hydroxychloroquine (Plaquenil) Leflunomide (Arava) Methotrexate (Otrexup, Rasuvo, RediTrex) Mycophenolate mofetil (CellCept) Sulfasalazine (Azulfidine) Tofacitinib (Xeljanz, Xeljanz XR) According to the Cleveland Clinic , common side effects of traditional DMARDs include: Loss of appetite Nausea Diarrhea Abdominal pain Rash, allergic reaction Liver problem Increased risk of infection Low blood cell counts Common side effects of biologic DMARDs include: Increased risk of common and serious infections Reactivation of tuberculosis, herpes zoster, and hepatitis B and C Increased cholesterol levels, increased liver enzymes and low blood cell counts Increased risk of clotting When prescribed DMARDs, inform your doctor of any other medications, including over-the-counter medicines, you are taking to avoid drug interactions. Some of these medications can cause teratogenicity (defects in a developing fetus.) Writing recently in the Journal of the American Academy of Physician Assistants (JAAPA ), physician assistant Michelle DiBiase and Dr. Samantha Kohn remind people that "The mainstay of pharmacologic therapy is early intervention with use of nonbiologic and biologic DMARDs together with adjunctive medications such as NSAIDs, oral and intra-articular corticosteroids, and analgesic medications, including opioids." Your primary care provider or rheumatologist will work closely with you to determine which medications are best for your treatment. It is vital to keep them apprised of any side effects and let them know if the treatment is ineffective. They can work with you to find a treatment that helps relieve the pain and inflammation caused by arthritis. Posted April 2023

Drug Approval

10 Nov 2008

·www.biospace.com

Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group Comprehensive Investor Relations and Media Outreach to Commence

LA JOLLA, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. ( ) (the "Company"), a specialty pharmaceutical company focused on developing and commercializing non-invasive, topically administered medications, has retained the Investor Relations Group ("IRG"), a thirteen-year-old, highly recognized corporate communications firm based in New York City, to serve as its investor relations and public relations firm. IRG will strive to increase the Company's public exposure and to communicate the advantages of its innovative proprietary transdermal delivery technology, Transdel(TM), its lead topical drug, Ketotransdel(TM) and its other drug candidates through a focused campaign. On the investor relations front, IRG will use its proprietary database of investors to introduce the Company to targeted members of the investment community through pre-qualified one-on-one introductions, e-mails to professionals that have opted-in to receive communication, interviews, and traditional outreach. In the public relations arena, IRG will educate audiences of editors, writers, and segment producers of local and national trade and consumer print, radio, on-line, and broadcast media outlets about the Company and its role in the market. The Company's lead topical drug, Ketotransdel(TM), utilizes their Transdel(TM) cream formulation to facilitate the passage of ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin barrier to reach targeted underlying tissue where the drug exerts its prolonged localized anti-inflammatory and analgesic effect. The Company is also investigating other novel and generic drugs and promising therapeutic areas in combination with using their patented transdermal delivery system. Furthermore, the Company is actively pursuing the development of cosmeceutical products. "With our lead product, Ketotransdel(TM), in Phase 3 clinical trial, and a strong pipeline of co-development opportunities utilizing our Transdel(TM) platform technology, this is an opportune time to increase our visibility within the investment and media community," said Dr. Juliet Singh, President and CEO of Transdel Pharmaceuticals. "As we remain focused on our clinical program and growth objectives, we look forward to IRG communicating our progress to the appropriate target audiences." About Transdel Pharmaceuticals, Inc. Transdel Pharmaceuticals, Inc. is a specialty pharmaceutical company developing non-invasive, topically-delivered medications. The Company's innovative patented proprietary Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of drugs through the tough skin barrier to reach the target underlying tissues. In the case of Ketotransdel(TM), the Transdel(TM) cream allows the active ingredient ketoprofen to reach the target soft tissue and exert its well-known anti-inflammatory and analgesic effects. The Company is also investigating other drug candidates and treatments for transdermal delivery using the patented Transdel(TM) platform technology for products in pain management and other therapeutic areas. For more information, please visit About The Investor Relations Group, Inc. The Investor Relations Group, Inc. (IRG) offers a full-service corporate communications program designed to suit the many unique needs of public companies. The program utilizes a proprietary, targeted approach to reach institutional investors, analysts, and the media-at-large. For further information, please visit the company's website at Safe Harbor Statement The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. CONTACT: John Lomoro, CFO of Transdel Pharmaceuticals, Inc., +1-858-457-5300, johnl@transdelpharma.com; or Investor Relations, Rachel Colgate or Michael Crawford, or Media Relations, Laura Colontrelle or Janet Vasquez, all of Investor Relations Group, Inc., +1-212-825-3210 Web site:

Financial StatementGeneric Drug

100 Deals associated with Ketoprofen

External Link

KEGG	Wiki	ATC	Drug Bank
D00132	Ketoprofen	M02AA10 M01AE03	DB01009

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Periarthritis	Japan	Hisamitsu Pharmaceutical Co., Inc.	06 Aug 2007
Tendinopathy	Japan	Hisamitsu Pharmaceutical Co., Inc.	06 Aug 2007
Tumescence	Japan	Hisamitsu Pharmaceutical Co., Inc.	01 Sep 1989
Analgesia	Japan	Kissei Pharmaceutical Co., Ltd.	29 Nov 1986
Inflammation	Japan	Kissei Pharmaceutical Co., Ltd.	29 Nov 1986
Osteoarthritis	United States	Wyeth-Ayerst Laboratories	09 Jan 1986
Pain	United States	Wyeth-Ayerst Laboratories	09 Jan 1986
Rheumatoid Arthritis	United States	Wyeth-Ayerst Laboratories	09 Jan 1986
Arthritis	China	Mudanjiang Lingtai Pharmaceutical Co. Ltd.	01 Jan 1986

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ankle Injuries	Phase 3	United States	Hisamitsu Pharmaceutical Co., Inc.	01 Apr 2008
Shoulder Pain	Phase 3	United States	Hisamitsu Pharmaceutical Co., Inc.	01 Apr 2008
Osteoarthritis, Knee	Phase 3	United States	Hisamitsu Pharmaceutical Co., Inc.	01 Sep 2007
Acute migraine	Phase 2	United States	Achelios Therapeutics, Inc.	01 Mar 2014
Temporomandibular Joint Disorders	Phase 2	-	Achelios Therapeutics, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EULAR2022	Not Applicable	Non-radiographic axial spondyloarthritis	43	Continuous NSAIDs intake	pzqbulivwr(kmtglokijp) = abuobctiwz unlytnnpey (lbkmziufqn ) View more	Positive	01 Jun 2022
				Occasional NSAIDs intake	ixuhoqjaun(iqualupyue) = uykazefgmm vycbvphebz (tnrhotswom )
WCO_IOF_ESCEO2020	Not Applicable	Osteoarthritis, Knee First line	23	Ketoprofen applications	lsfpfojdwi(kupoyihari) = nccczxkkje njslolopaz (khzfrbnauy ) View more	Positive	20 Aug 2020
NCT02568644 (CTgov)	Not Applicable	Migraine Disorders	60	Extract of ginger+Intravenous ketoprofen (Extract of Ginger)	nfcvfgkfju(kaurgapknm) = rarahtzymj yhwqpgpszo (rwzzvywqpf, 0.04) View more	-	07 Apr 2020
				Cellulose+Intravenous ketoprofen (Cellulose)	nfcvfgkfju(kaurgapknm) = utlstxsler yhwqpgpszo (rwzzvywqpf, 0.07) View more
NCT01893879 (PCTTPL, CTgov)	Not Applicable	Solid tumor \| Lymphedema	14	laboratory biomarker analysis+(RS)2-(3-benzoylphenyl)-propionic acid ((RS)2-(3-benzoylphenyl)-Propionic Acid)	leoaemfjia = wfaeljqtfr uqsggsokqw (gtzfwbufxe, myfxcalacg - cpwtcuslnf) View more	-	18 May 2017
				placebo for study drug (Placebo for Study Drug)	leoaemfjia = bpqmfhchpb uqsggsokqw (gtzfwbufxe, tsfiqlshxh - bzttvrvyng) View more
NCT02099006 (Topicals, CTgov)	Phase 2/3	Vulvodynia \| Genital Diseases, Female \| Reproductive tract disorder NOS	9	Baclofen+Amitriptyline+ketoprofen+Loperamide+Ketamine+Gabapentin (Medications)	sqiemrwfez(cbcunlvdbe) = ptbwwoitaz vgnbwhczox (vwmgzvwmny, 1.94) View more	-	15 Jul 2016
				placebo (Placebo)	sqiemrwfez(cbcunlvdbe) = qymwuhpnqw vgnbwhczox (vwmgzvwmny, 2.3) View more
UEGW2014	Not Applicable	Post-ERCP acute pancreatitis	-	Ketoprofen 100mg	exqhladmwa(pkqedrvaaq) = mtbdejweml qpgsobdgaw (pfklbcehnx )	-	01 Oct 2014
				Placebo	exqhladmwa(pkqedrvaaq) = pejjhxfqql qpgsobdgaw (pfklbcehnx )
NCT00553605 (NAP, CTgov)	Phase 4	Renal Colic	340	Parecoxib (Parecoxib)	jdxbaqowdb(lrpnmazqvp) = eauspobiaf bpepeolrbb (cuoubqgovl, 3.35) View more	-	28 Jan 2013
				Ketoprofen (Ketoprofen)	jdxbaqowdb(lrpnmazqvp) = qvqtjjitjr bpepeolrbb (cuoubqgovl, 3.46) View more
DIRACTIN (EULAR2009)	Not Applicable	Osteoarthritis, Knee	-	Diractin® 100 mg ketoprofen	xignjnezqy(ifxagmqxuz) = vfjkryjdig xbuohinbrg (yydtrulgrq ) View more	Positive	10 Jun 2009
				Placebo	xignjnezqy(ifxagmqxuz) = jphzdrytzy xbuohinbrg (yydtrulgrq ) View more
EULAR2007	Phase 3	Osteoarthritis, Knee	866	Placebo	owxdzrkacb(tmddugvypt) = The majority of treatment related adverse events (AE) were dermal AE including erythema (8.6% with 100mg, 8.1% with 50mg, 3.6% with 25 mg ketoprofen and 4.5% with placebo). Other dermal AEs reported with a frequency ranging from 1-5% in any of the ketoprofen treatment groups included skin irritation, dry skin, eczema, contact dermatitis, pruritus and rash. Other AEs had an incidence rate below 1%. rarhmhfxzp (zvmiktrnfj )	Positive	13 Jun 2007
				25 mg ketoprofen in IDEA-033
EULAR2006	Not Applicable	Osteoarthritis, Knee	397	IDEA-033 (Ketoprofen in Transfersome® Gel)	dtapotagfd(zssmpfmgga) = Overall, 53.6% of subjects treated with IDEA-033, 50.0% of subjects treated with celecoxib, and 48.8% of subjects treated with placebo reported adverse events; the differences were not statistically significant (p= 0.7116) mzavsgxivs (hwxuefjmjy )	Positive	21 Jun 2006
				Celecoxib

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ketoprofen

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation